SCHEMBL1993929

SCHEMBL1993929

CCc1nc2c(=O)[nH]cnc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.40
ADORA1 P30542 2/20 0.40
ADORA3 P0DMS8 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
KDM4A O75164 1/20 0.39
KDM4B O94953 1/20 0.39
KDM5C P41229 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDPK1 O15530 2/20 0.37
PDE4A P27815 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20830316 0.82 TSHR (0.39) ADORA2ACYP1A2CYP2D6ALDH1A1KDM4A
SCHEMBL1992700 0.77 PARP1 (0.41) ADORA2ACYP1A2CYP2D6ALDH1A1RAB9A
SCHEMBL11133896 0.76 ADORA2A (0.47) ADORA2AADORA1ADORA3ALDH1A1KDM4E
SCHEMBL19181967 0.74 PNP (0.37) CYP1A2CYP2D6RAB9AKDM4EGAA
SCHEMBL22487751 0.73 CYP1A2 (0.33) ADORA2AADORA1ADORA3CYP1A2CYP2D6
SCHEMBL10518128 0.73 ALDH1A1 (0.53) ADORA2AADORA3ALDH1A1GLARAB9A
SCHEMBL3941170 0.73 ACHE (0.40) ADORA2AADORA3CYP1A2CYP2D6ALDH1A1
SCHEMBL22487730 0.72 ACHE (0.37) ADORA2ACYP1A2CYP2D6ALDH1A1RAB9A
SCHEMBL22487750 0.72 HPGD (0.42) ADORA2ACYP1A2CYP2D6L3MBTL1ALDH1A1
Hypoxanthine SCHEMBL822613 0.71 TSHR (0.47) ADORA2AALDH1A1TNKS2RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists MERCK SHARP & DOHME LTD. (GB) 2011-06-23 US disclosed
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed
US-20070135454-A1 Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) BAYLISS TRACY 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 ADORA2A 495/4885ADORA1 351/4885ADORA3 507/4885
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists NR2C2, NR3C2, NR2E3 ADORA2A 789/4885ADORA1 283/4885ADORA3 289/4885
US-20070135454-A1 Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) TRPV1, TRPV2, TRPV4 ADORA2A 536/4885ADORA1 339/4885ADORA3 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.